Baxter

Suprane
(DESFLURANE)

Suprane in an Aluminium bottle
An Evolution in Packaging



Baxter

Abbreviated Prescribing information
SUPRANE (Desflurane, USP)
Presentation: Suprane (desflurane, USP) is a colourless, volatile liquid for inhalation containing 100% desflurane. **Indications:** Inhalation agent for induction and/or maintenance of anaesthesia in adults, maintenance of anaesthesia in paediatrics. **Dosage and administration:** See PI for full details. Administration by inhalation using vapouriser specifically designed for use with desflurane and dose individualised based on patient's response. MAC decreases with increasing age. Induction: 4-11 % usually produces surgical anaesthesia in 2-4 minutes (not paediatrics). Maintenance : 2-6% with concomitant nitrous oxide or 2.5-8.5% in oxygen or enriched air. Concentrations of 1-4% have been used successfully in chronic renal/hepatic impairment and renal transplant. **Side effects:** Common (≥1/100-<1/10) Pharyngitis, breath holding. Headache, conjunctivitis, nodal arrhythmia, bradycardia, tachycardia, hypertension, apnea, cough, laryngospasm, salivary hypersecretion, increased creatinine phosphokinase, ECG abnormal. **Warning and Precautions:** only to be administered by people trained in administration of general anaesthesia with appropriate emergency measures available. Monitor Blood pressure and heart rate as part of evaluation of the depth of anaesthesia. Caution in use with LMA or face mask in children under 6 years. May trigger malignant hyperthermia. Inhaled anaesthetics have been associated with increases in serum potassium. May increase CSF pressure . Carbon dioxide absorbers should not dry out. Appropriate analgesia should be administered at the end of surgery or early in PACU. **Contra-indications:** Not to be used if general anaesthesia in contra-indicated, Known hypersensitivity to halogenated agents or known susceptibility to malignant hyperthermia. Contraindicated for use as an inhalation induction agent in pediatric. **Interactions:** MAC reduced by concomitant N_2O administration. Neuromuscular blocks are potentiated by desflurane. Concomitant administration of opioids or benzodiazepines show a marked reduction in MAC **Overdose:** Discontinue desflurane, establish clear airway and initiate assisted/controlled ventilation with pure oxygen. Support and maintain adequate haemodynamics. **Legal category:** POM **Date of Preparation:** September 2021

Baxter Healthcare (Thailand) Co.,Ltd.
11th Floor, Thanapoom Tower, 1550 New Petchburi Road, Makasan,
Rajthevi, Bangkok 10400 Thailand. Tel 02-667-0505, Fax 02-662-7770

โปรดอ่านรายละเอียดเพิ่มเติมในเอกสารกำกับยา
ใบอนุญาตโฆษณาเลขที่ ฆศ. 1198/2564